{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:17:21Z","timestamp":1789917441351,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.semarthrit.2015.10.013","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T15:58:07Z","timestamp":1446652687000},"page":"698-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A review of the effects of statins in systemic sclerosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Karim","family":"Ladak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.10.013_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/01.bor.0000245720.02512.3e","article-title":"Potential benefits of statins for vascular disease in systemic sclerosis","volume":"18","author":"Kuwana","year":"2006","journal-title":"Curr Opin Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/08916930903002487","article-title":"Mechanisms of vascular damage in systemic sclerosis","volume":"42","author":"Muller-Ladner","year":"2009","journal-title":"Autoimmunity"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2015.10.013_bib3","first-page":"iii3","article-title":"Overview of pathogenesis of systemic sclerosis","volume":"48","author":"Abraham","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2007.11.044","article-title":"Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women","volume":"51","author":"Rossi","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/art.30380","article-title":"Atherosclerosis in systemic sclerosis\u2013a systematic review and meta-analysis","volume":"63","author":"Au","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"23 Suppl 1","key":"10.1016\/j.semarthrit.2015.10.013_bib6","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib7","doi-asserted-by":"crossref","first-page":"12216","DOI":"10.1016\/S0021-9258(18)98884-8","article-title":"Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation","volume":"266","author":"Chakrabarti","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cardiores.2004.09.014","article-title":"HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation","volume":"64","author":"Azuma","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2003.10.002","article-title":"HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis","volume":"172","author":"Yilmaz","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nri1839","article-title":"Statin therapy is autoimmunity: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognised type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib12","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.4049\/jimmunol.180.10.6988","article-title":"Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes","volume":"180","author":"Zhang","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.4049\/jimmunol.172.2.1273","article-title":"Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy","volume":"172","author":"Nath","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/ar3445","article-title":"Cardiovascular disease in systemic sclerosis\u2014an emerging association?","volume":"13","author":"Ngian","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.amjmed.2013.06.025","article-title":"Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study","volume":"126","author":"Chu","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib17","first-page":"S905","article-title":"Atorvastatin attenuates skin fibrosis through the PI3K pathway","volume":"63","author":"Ota","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib18","article-title":"Influence of atorvastatin on normal and scleroderma fibroblast activation and type 1 collagen production","volume":"44","author":"Del Papa","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib19","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.21723","article-title":"Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin","volume":"54","author":"Louneva","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket144","article-title":"Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis","volume":"52","author":"Bagnato","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib21","article-title":"Simvastatin modulates aortic intima\/media thickness in an animal model of systemic sclerosis","volume":"32","author":"Bagnato","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib22","first-page":"S167","article-title":"Endothelial dysfunction and inflammation markers dynamics during atorvastatin treatment in systemic sclerosis","volume":"28","author":"Alekperov","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib23","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib24","first-page":"1323","article-title":"Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial 867 repair in systemic sclerosis","volume":"35","author":"Del Papa","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib25","first-page":"51","article-title":"Clinical efficiency of rosuvastatin in patients with systemic scleroderma","author":"Yatsyshyn","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/s10165-009-0199-4","article-title":"Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis","volume":"19","author":"Kuwana","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib27","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1007\/s00296-011-2183-5","article-title":"Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients","volume":"32","author":"Rossi","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib28","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar4285","article-title":"Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis\u2014a prospective case-series study","volume":"15","author":"Timar","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/ard.2005.046870","article-title":"Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study","volume":"65","author":"Furukawa","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/keq003","article-title":"Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis","volume":"49","author":"Sadik","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib31","first-page":"S158","article-title":"Simvastatin in systemic sclerosis patients\u2014an open-label study","volume":"28","author":"Ionitescu","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib32","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/art.21899","article-title":"Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis","volume":"54","author":"Kuwana","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib33","first-page":"200","article-title":"Short therapy with simvastatin improves endothelial function in patients affected by systemic sclerosis","volume":"66","author":"Bazzichi","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib34","first-page":"384","article-title":"Twelve-weeks therapy with fluvastatin improves brachial arterial endothelium-dependent vasodilation in patients with systemic sclerosis","volume":"65","author":"Beretta","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib35","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/acr.20598","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib36","first-page":"S122","article-title":"The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review","volume":"31","author":"Muangchan","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/157018006776286998","article-title":"Inhibition of geranyl-geranyl prenylation by statins: a novel model of disease modification of systemic sclerosis","volume":"3","author":"Derk","year":"2006","journal-title":"Letters Drug Des Discov"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/BOR.0b013e32834b1606","article-title":"New insights on chemically induced animal models of systemic sclerosis","volume":"23","author":"Batteux","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.autrev.2005.06.010","article-title":"Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?","volume":"5","author":"Derk","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.0000134644.89917.96","article-title":"Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis","volume":"95","author":"Distler","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib41","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar596","article-title":"Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers","volume":"4","author":"Distler","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2008.091918","article-title":"EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells","volume":"68","author":"Distler","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib43","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/art.22035","article-title":"Bone marrow endothelial progenitors are defective in systemic sclerosis","volume":"54","author":"Del Papa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib44","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3899\/jrheum.091346","article-title":"Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis","volume":"37","author":"Del Papa","year":"2010","journal-title":"J Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib45","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hh1301.093953","article-title":"Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease","volume":"89","author":"Vasa","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1172\/JCI200113131","article-title":"HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells","volume":"108","author":"Llevadot","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib47","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease","volume":"103","author":"Vasa","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/01.RES.0000070067.64040.7C","article-title":"HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes","volume":"92","author":"Assmus","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib49","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/eurheartj\/ehq340","article-title":"Assessment of atherosclerosis: the role of flow-mediated dilatation","volume":"31","author":"Charakida","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3899\/jrheum.091116","article-title":"Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment","volume":"37","author":"Rollando","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2249.2012.04564.x","article-title":"Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells","volume":"168","author":"Iwata","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2004.07.003","article-title":"Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients","volume":"177","author":"Ascer","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","article-title":"Strong decrease of high sensitivity C-reactive protein with highdose atorvastatin in patients with type 2 diabetes mellitus","volume":"166","author":"van de Ree","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib54","doi-asserted-by":"crossref","first-page":"31725","DOI":"10.1074\/jbc.272.50.31725","article-title":"Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase","volume":"272","author":"Laufs","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2001-14843","article-title":"Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules","volume":"109","author":"Mueck","year":"2001","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cardiores.2003.11.032","article-title":"Simvastatin reduces atrial myofibroblast proliferation independent of cholesterol lowering via inhibition of RhoA","volume":"61","author":"Porter","year":"2004","journal-title":"Cardio Res"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib57","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar1968","article-title":"Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts","volume":"8","author":"Connor","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib58","article-title":"Abstract 4145: effects of statin and niacin therapy on flow mediated dilation and high sensitivity C-reactive protein in patients with the metabolic syndrome","volume":"114","author":"Cheema","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/clc.4960250610","article-title":"Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy","volume":"25","author":"Frick","year":"2002","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacc.2013.09.017","article-title":"Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease","volume":"63","author":"Han","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jacc.2013.04.105","volume":"63","author":"Leoncini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib62","article-title":"A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation","author":"Purvesh Khatri","year":"2013","journal-title":"JEM"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib63","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjmed.2012.04.011","article-title":"Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis","volume":"125","author":"Chopra","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib65","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/cid\/cis733","article-title":"Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes","volume":"55","author":"Mortensen","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2015.10.013_bib66","unstructured":"Personal correspondence from Dr. Murray Baron, director of the Canadian Scleroderma Research Group. [accessed 17.06.15]."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:01:20Z","timestamp":1653454880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215002747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0049017215002747"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the effects of statins in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}